纳米载体
淋巴瘤
B细胞淋巴瘤
癌症研究
CD22
免疫系统
B细胞
医学
免疫学
药理学
抗体
CD20
药品
作者
Qixiong Zhang,Shanshan Li,Kun Guo,Xiaohong Yin,Rongsheng Tong
标识
DOI:10.1016/j.actbio.2022.06.033
摘要
B-cell lymphoma is one of the most common types of lymphoma, and chemotherapy is still the current first-line treatment. However, due to the systemic side effects caused by chemotherapy drugs, traditional regimens have limitations and are difficult to achieve ideal efficacy. Recent studies have found that CD22 (also known as Siglec-2), as a specific marker of B-cells, is significantly up-regulated on B-cell lymphomas. Inspired by the specific recognition and binding of sialic acid residues by CD22, a polysialic acid (PSA)-modified PLGA nanocarrier (SAPC NP) designed to target B-cell lymphoma was fabricated. Mitoxantrone (MTO) was further loaded into SAPC NP through hydrophobic interactions to obtain polysialylated immunogenic cell death (ICD) nanoinducer ([email protected] NP). Cellular experiments confirmed that [email protected] NP could be specifically taken up by two types of CD22+ B lymphoma cells including Raji and Ramos cells, unlike the poor endocytic performance in other lymphocytes or macrophages. [email protected] NP was determined to enhance the ICD and show better apoptotic effect on CD22+ cells. In the mouse model of B-cell lymphoma, [email protected] NP significantly reduced the systemic side effects of MTO through lymphoma targeting, then achieved enhanced anti-tumor immune response, better tumor suppressive effect, and improved survival rate. Therefore, the polysialylated ICD nanoinducer provides a new strategy for precise therapy of B-cell lymphoma. • Polysialic acid functionalized nanocarrier (SAPC NP) was designed and prepared. • SAPC NP is specifically endocytosed by two CD22+ B lymphoma cells. • Mitoxantrone-loaded nanoinducer ([email protected] NP) promote immunogenic cell death and anti-tumor immune response. • “Polysialylation” is a potential new approach for precision treatment of B-cell lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI